NASDAQ:PTGX

Protagonist Therapeutics Q1 2025 Earnings Results & Report

Protagonist Therapeutics logo
$124.67 -0.16 (-0.13%)
Closing price 04:00 PM Eastern
Extended Trading
$124.75 +0.08 (+0.06%)
As of 05:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Protagonist Therapeutics beat analyst earnings expectations but missed on revenue in its Q1 2025 results, released May 6, 2025. The company reported EPS of -$0.19 versus the -$0.50 consensus estimate, while revenue of $28.32 million fell short of the $30.44 million estimate by $2.12 million.

Earnings Announcement Details

Quarter
Q1 2025
Report Date
Time
Before Market Opens
Conference Call
12:00 AM ET

Protagonist Therapeutics EPS Results

Actual EPS
-$0.19
Consensus EPS
-$0.50
Beat/Miss
Beat by +$0.31
One Year Ago EPS
N/A
EPS Beat Rate
5 of last 8 quarters

Protagonist Therapeutics Revenue Results

Actual Revenue
$28.32 million
Expected Revenue
$30.44 million
Beat/Miss
Missed by -$2.12 million
YoY Revenue Growth
N/A

Protagonist Therapeutics Q1 2025 Earnings FAQ

Protagonist Therapeutics (NASDAQ:PTGX) reported earnings of -$0.19 per share for Q1 2025, beating the consensus estimate of -$0.50. The report was announced on Tuesday, May 6, 2025.

Protagonist Therapeutics reported revenue of $28.32 million for Q1 2025, against a consensus estimate of $30.44 million.

Protagonist Therapeutics Earnings Headlines

HC Wainwright Has Optimistic Opinion of PTGX FY2026 Earnings
You missed yesterday's deadline…
In June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times the output of Saudi Arabia's largest oil well, enough potential energy to power civilization for two million years. While the One Big Beautiful Bill Act stripped tax credits from solar, wind, and EVs on July 4th, this discovery was reclassified alongside oil and nuclear and secured eight years of credits. Google signed a 15-year contract, and Bill Gates committed 100 million dollars.tc pixel
Protagonist Therapeutics (NASDAQ:PTGX) Price Target Raised to $221.00
See More Protagonist Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Protagonist Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Protagonist Therapeutics and other key companies, straight to your email.

About Protagonist Therapeutics

Protagonist Therapeutics (NASDAQ:PTGX) is a clinical-stage biopharmaceutical company that discovers and develops peptide-based medicines, primarily for inflammatory and blood disorders. Its research approach uses engineered peptides designed to act on specific biological targets.

The company’s programs include rusfertide, a hepcidin mimetic being developed for polycythemia vera, and icotrokinra, an oral interleukin-23 receptor antagonist being developed for immune-mediated diseases. Protagonist has entered into licensing and development collaborations for these programs with Takeda and Johnson & Johnson, respectively; they are investigational medicines, not approved treatments.

Founded in 2006 and based in Newark, California, Protagonist is led by co-founder and Chief Executive Officer Dinesh V. Patel, Ph.D.

View Protagonist Therapeutics Profile